The FDA has started a priority review of GSK's gepotidacin, which could become the first in a new class of oral antibiotics ...

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an ...

▎药明康德内容团队编辑GSK今天宣布，美国FDA已接受其潜在"first-in-class"口服抗生素gepotidacin的新药申请（NDA），用于治疗患有单纯性尿路感染（uUTI，也称为急性膀胱炎）成年或青少年（≥12岁）女性患者，患者体重须≥4 ...

Application supported by positive results from pivotal phase III EAGLE-2 and EAGLE-3 trials26 March 2025 assigned as action date for FDA decisionGepotidacin could be the first in a new class of oral ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

GSK plc (GSK, GSK.L) announced the FDA has accepted the New Drug Application for gepotidacin, an oral antibiotic with a mechanism of ...

(Alliance News) - GSK PLC on Wednesday announced that the US Food & Drug Administration has accepted its New Drug Application for gepotidacin. The London-based biopharma company said the FDA has ...

GSK announced on Wednesday that the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for gepotidacin, a first-in-class oral antibiotic, under priority review.

London open The FTSE 100 is expected to open 17 points higher on Wednesday, having closed down 0.52% on Tuesday at 8,249.28.

GSK said that its urinary tract infections treatment gepotidacin has been accepted for priority review by the U.S.'s Food and Drug Administration.

Stocks were higher in London on Wednesday morning, as data showed that UK consumer price inflation fell in September to its lowest rate in more than three years, while producer prices decreased. In ...

The European stock markets closed mostly lower in Wednesday trading as the Stoxx Europe 600 was off 0.15%, the Swiss Market Index declined 0.21%, France's CAC dropped 0.40%, Germany's DAX was down ...